Slides
Page 1
J.P. Morgan Healthcare Conference Dan Scavilla President and Chief Executive Officer January 13, 2026
Page 2
Forward-Looking Statements and Associated Risks This presentation contains statements that do not directly and exclusively relate to historical facts which constitute forward-looking statements, including, statements and projections concerning, among other things, the Company’s return-to-growth action plan described in this presentation and statements and projections regarding the Company’s use of technology to drive change to its business, including enhanced operational and financial performance. The Company’s forward-looking statements represent current expectations and beliefs and involve risks and uncertainties. Actual results may differ significantly from those projected or suggested in any forward-looking statements and no assurance can be given that the results described in such forward-looking statements will be achieved. Investors are cautioned not to place undue reliance on such forward-looking statements which speak only as of the date they are made. The forward-looking statements are subject to numerous assumptions, risks and uncertainties and other factors that could cause actual results to differ materially from those described in such statements, many of which are outside of our control. The Company does not undertake any obligation to release publicly any revisions to such forward-looking statements to reflect events or circumstances occurring after the date hereof or to reflect the occurrence of unanticipated events. Any number of factors could cause the Company’s actual results to differ materially from those contemplated by any forward-looking statements, including, but not limited to, the risks associated with the following: the Company’s ability to remain profitable in a very competitive marketplace, which depends upon the Company’s ability to differentiate its products and services from those of competitors; the Company’s failure to realize assumptions and projections which may result in the need to record additional impairment charges; the effect of changes to the Company’s distribution channels for its products and the failure of significant distributors of the Company to effectively manage their inventories; increased regulation that impacts the Company’s business; the Company’s ability to control costs and failure to realize expected benefits of cost reduction and restructuring efforts and the Company’s failure to anticipate and appropriately adapt to changes or trends within the rapidly changing dental industry, and the Company’s ability to execute on its return-to-growth action plan. Investors should carefully consider these and other relevant factors, including those risk factors in Part I, Item 1A, (“Risk Factors”) in the Company’s most recent Form 10-K, including any amendments thereto, and any updating information which may be contained in the Company’s other filings with the SEC, when reviewing any forward-looking statement. The Company notes these factors for investors as permitted under the Private Securities Litigation Reform Act of 1995. Investors should understand it is impossible to predict or identify all such factors or risks. As such, you should not consider either the foregoing lists, or the risks identified in the Company’s SEC filings, to be a complete discussion of all potential risks or uncertainties. Non-GAAP Financial Measures In addition to results determined in accordance with U.S. generally accepted accounting principles (“US GAAP”) the Company provides certain measures in this presentation, described below, which are not calculated in accordance with US GAAP and therefore represent Non-GAAP measures. These Non-GAAP measures may differ from those used by other companies and should not be considered in isolation from, or as a substitute for, measures of financial performance prepared in accordance with US GAAP. These Non-GAAP measures are used by the Company to measure its performance and may differ from those used by other companies. Management believes that these Non-GAAP measures are helpful as they provide a measure of the results of operations, and are frequently used by investors and analysts to evaluate the Company’s performance exclusive of certain items that impact the comparability of results from period to period, and which may not be indicative of past or future performance of the Company. The Company does not provide forward-looking estimates on a GAAP basis as certain information is not available and cannot be reasonably estimated.
Page 3
Agenda 1 2 3 4 5 Dentsply Sirona Overview The Markets We Compete In Product Portfolio and Connected Dentistry Return-to-Growth Action Plan Progress Q&A 3
Page 4
Dentsply Sirona: Leader in Connected Dentistry Connected dentistry enables technology, collaboration, and patient-centered care to converge in new ways Essential Dental Solutions 38% Connected Technology Solutions 28% Wellspect Healthcare 8% Orthodontic and Implant Solutions 26% United States 36% Europe 40% Rest of World 24% Key Statistics 100+ Countries Served 40+ Years Since Inventing Single-Visit Dentistry 4 Sales by Segment1 Sales by Region1 400k+ Average Dental Professionals Trained Annually 50+ New Products Launched in Last Four Years 1Net Sales as of FY2024
Page 5
Essential Dental Solutions Wellspect Healthcare ▪ Aging population, middle class expansion, and rising aesthetic expectations ▪ Digital dentistry adoption driving innovation and efficiency ▪ General Practitioners expanding into specialty procedures ▪ Improving patient access to oral care Orthodontic & Implant Solutions ▪ Demographic trends ▪ Increased therapy awareness ▪ Expanding into new markets Connected Technology Solutions ~$7B ~$8B ~$15B ~$3B 5 Intraoral Scanners Mills and Printers Imaging Treatment Centers Instruments Endodontics Restorative Preventive Clear Aligners Implants Regenerative and Lab Materials Urology Enterology Global Market Size Key Product Categories Market Dynamics Source: management estimates, iData, public reports Reporting Segments Operating in an Attractive $33B Market with a 3-4% CAGR
Page 6
Wellspect Healthcare $0.3B Net Sales Orthodontic & Implant Solutions (OIS) Essential Dental Solutions (EDS) $1.5B Net Sales Connected Technology Solutions $1.1B Net Sales Positions of Strength in EDS and Chairside with Opportunities to Accelerate in OIS 6 Market Positions DS Core Primescan Primemill Axano Featured Brands Dental Segments Healthcare Cavitron Nupro CEREC Cercon 4D WaveOne Gold Astra Tech Implant EV MIS Atlantis SureSmile LoFric Navina #1 Full-Chairside #2 Imaging #3 IOS + Treatment Centers & Instruments #1 Preventive #1 Endodontics #2 Restorative #4 Implants & Prosthetics #5 Clear Aligners #2 Continence Care Net Sales Figures as of FY2024 Source: management estimates, iData, public reports $1.0B Net Sales $0.8B Net Sales ex-Byte
Page 7
Addressing the Unmet Needs of the Dentist Through Connected Dentistry and DS Core Workflows Source: 1 2022, BCG, Dentistry.co.uk; 2 2024, American Dental Association, Q1 panel report; 3 The 2022 Dental Industry Report, Dandy; 4 2024, DS internal research; 5 2024, DS Internal Brand Equity Research. Available at contact@dentsplysirona.com. 7 Dentists’ challenges of patients don’t accept the dental treatment proposed by their dentists1 Low treatment acceptance 54 % of dentists don’t manage to treat all their patients or overwork themselves2 Operational constraints 36 % of dentists see cost as a key barrier for further adopting digital dentistry5 IT costs & complexity 79 % Dentists’ priorities of dentist’s report increasing practice profitability as top priority3 Growing practice 65 % of dentists see improved efficiency a key reason to adopt digital dentistry4 Efficient operations 54 % of dentists see better patient experience as a key reason for adopting digital dentistry5 Excellent patient outcomes 71 % CONNECTED DENTISTRY
Page 8
Streamlining Practice Workflows from Scan to Treatment Through Connected Dentistry Well-positioned to be a partner of choice across one integrated ecosystem Implantology Orthodontics Endodontics Restorative Practices Use Various Systems Across Their Treatment Pathways 8
Page 9
Leading the Way in Single-Visit Dentistry: One Hour. One Visit. Simplifying Workflows Consultation, diagnosis, design & manufacturing in one platform Shortening Design Time AI-generated proposals & guided workflows that support every skill level Lowering the Barrier to Entry CEREC Go designed with minimal complexity and lower upfront cost Unlocking New Opportunities Enabling practices to do same day, single-visit dentistry Scan Diagnose Plan Make Treat Indirect restorations account for ~30% of office revenue (U.S.) 2 of 3 patients would switch their dentist to receive a single-visit dentistry treatment1 1Dynata Research. January 9, 2020. 9
Page 10
Future DS Core Applications: Connected Dentistry Enhances the Practice of Dentistry Implantology Streamline your workflow and simplify communication with treatment team Comprehensive Orthodontics Increase patient conversion Endodontics Get the full picture effortlessly and communicate with confidence Restorative Optimize collaboration with your lab or rationalize your chairside workflow Delivering Growth, Efficiency and Outcomes 10
Page 11
Return-to-Growth Action Plan Update 11
Page 12
Return-to-Growth Action Plan Initiated November 2025 Customer Centric Mindset • Creating strategic KOL Advisory Boards supporting CEO • Expanding global clinical education program investment to $40M • Enhancing dentist engagement in R&D process • Developing sales education focused on workflows facilitating connected dentistry by +$5M 1 Reigniting Sustainable Growth • Accelerating innovation through a double-digit increase in R&D over 24 months • Driving U.S. turnaround while investing in continued EMEA growth • Unifying commercial functions around market needs under new CCO • Re-engaging and expanding the U.S. dealer network to drive broader equipment adoption 2 Empowering Performance • Created Transformation Office driving Return- to-Growth action plan • Enabling quicker decisions and faster execution by streamlining processes • Advancing enterprise AI strategy to drive efficiencies • Establishing data analytics team to improve insights 3 Scaling Organization • Unlocking +$100M in P&L improvement to fuel Return-to-Growth action plan • Rationalizing legal entities, IT systems, and support functions through Centers of Excellence • Consolidating the supply chain for efficiency & scalability 4 Financial Strength • Developing capital allocation programs to enhance shareholder returns • Improving free cash flow and reducing inventory levels by 20% • Implementing tax strategy to enhance shareholder return 5 12
Page 13
Key Accomplishments Since Q3'25: 13 ✓ Signed distributor expansion agreement with Benco ✓ Named Mark Bezjak new Group Vice President, Americas Regional Commercial Organization ✓ Aligned commercial teams vertically to match the way the market operates ✓ Hired interim CFO Michael Pomeroy ✓ Implemented Transformation Office to execute on Return- To-Growth action plan ✓ Embedded accountability into daily operations, fostering a culture of ownership for outcomes ✓ Appointed Don Zurbay to Board of Directors ✓ Established Growth and Value Creation Board Committee Committed to providing ongoing updates to investors as key milestones are achieved during the year
Page 14
“ In Summary Market-leading positions built on an integrated portfolio that maximizes strengths across product categories and geographies Shaping the future of dentistry through connected dentistry Executing with urgency and accountability on Return-to-Growth action plan 14 Operating within a highly attractive $33B market